Brandon BioCatalyst, in partnership with ANDHealth, has been selected by the Australian Federal Government to deliver the A$50m (US$33.3m) BioMedTech Incubator (BMTI) programme. The investment, from the A$20bn Medical Research Future Fund (MRFF), substantially increases the grant funding available through existing Brandon BioCatalyst and ANDHealth programmes to more than A$115m. The BMTI programme will leverage the…
Home Healthcare Markets International Business Australia: Brandon BioCatalyst and ANDHealth selected for BMTI programme